Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adenovirus-transfected autologous dendritic cell vaccine + cytokine-induced killer cells
- Development stage
- Unknown
- Lead developer
- 307 Hospital of the People's Liberation Army
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Subcutaneous, Intravenous
01
Overview
A combination immunotherapy approach consisting of autologous dendritic cells (DCs) that have been genetically modified using adenoviral vectors to express tumor-associated antigens (such as MART-1, p53, MUC1, or Survivin), combined with cytokine-induced killer (CIK) cells. The DC vaccine component presents tumor antigens to activate specific T cell responses, while CIK cells provide direct tumor-killing activity through both MHC-restricted and non-MHC-restricted mechanisms. This dual approach aims to enhance overall anti-tumor efficacy compared to either component alone.
- Other names
- DC-CIKgmDCs-CIKdendritic cell-cytokine-induced killer cell therapy
02
Targets
MUC1 (Mucin-1 Antigen)BIRC5 (Survivin)
Beyond the preview
Go deeper on adenovirus-transfected autologous dendritic cell vaccine + cytokine-induced killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adenovirus-transfected autologous dendritic cell vaccine + cytokine-induced killer cells.